Pain Therapeutics, Inc. (NASDAQ:PTIE) registered a 11.93% increase, still its new closing price is 22.88% up from the company’s 1 year high of 3.00.It posted 13.94% gains in previous 5 sessions and is now the subject of 1 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 0 buy or better ratings. The 2 stock analysts following this company have an average price target at $1.75, with individual PT in the $1.75-$1.75 range. The shares moved at $0.63, implying that brokerage firms see shares losing about -62.69% in twelve months time.
Pain Therapeutics, Inc. (PTIE) SEC Form 4 News
The stock is getting much attention these days as insiders are adding shares while they posted a 9.93% rise year to date. A Director at Pain Therapeutics, Inc. (PTIE) acquired shares in a transaction closed on Wednesday November 06, 2013. ROBERTSON SANFORD bought 50,000 shares in the company at $3.73 each and collected $186,001 in proceeds. ROBERTSON SANFORD now owns 369,727 shares in the company after this transaction. A COO in the company, FRIEDMANN NADAV, disclosed a transaction on Tuesday October 18, 2011 that ended up generating $111,000 from the sale of 25,000 shares at $4.44 per share.
Pain Therapeutics, Inc. (NASDAQ:PTIE) Upcoming Results on Tap
Pain Therapeutics, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.10 in that period. Sales during the quarter are predicted to arrive at $0.
Earnings surprise history: Last quarter, the company posted approximately $0 in revenue and EPS of $-0.08. The mean forecast was for $0 and $-0.09 a share, respectively. One quarter earlier, revenue for the stock was at $0, with earnings at $-0.07/share.
Pain Therapeutics, Inc. (PTIE) Brokerage Update
Pain Therapeutics, Inc. (PTIE) is in Gabelli & Co’s research list so their analyst rating change is noteworthy. These shares were downgraded to Hold from Buy by Gabelli & Co, according to news reported on Tuesday September 13, 2016.Another important research note was issued by Credit Suisse on Friday April 17, 2009.The firm upgraded PTIE to Neutral from Underperform. Over the last six months and over the last three months, the shares of Pain Therapeutics, Inc. (PTIE), have changed -76.70% and 11.47%, respectively.